Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations

Publication date: Available online 5 April 2018
Source:Cancer/Radiothérapie
Author(s): J. Langrand-Escure, R. de Crevoisier, C. Llagostera, G. Créhange, G. Delaroche, C. Lafond, C. Bonin, F. Bideault, P. Sargos, S. Belhomme, D. Pasquier, I. Latorzeff, S. Supiot, C. Hennequin
Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques.



https://ift.tt/2GVKhQf